International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(13), P. 6951 - 6951
Published: June 25, 2024
Neurodegenerative
diseases
(NDs)
represent
an
unsolved
problem
to
date
with
ever-increasing
population
incidence.
Particularly,
Alzheimer's
disease
(AD)
is
the
most
widespread
ND
characterized
by
accumulation
of
amyloid
aggregates
beta-amyloid
(Aβ)
and
Tau
proteins
that
lead
neuronal
death
subsequent
cognitive
decline.
Although
neuroimaging
techniques
are
needed
diagnose
AD,
investigation
biomarkers
within
body
fluids
could
provide
important
information
on
neurodegeneration.
Indeed,
as
there
no
definitive
solution
for
monitoring
these
strategic
importance
they
useful
both
diagnosing
AD
assessing
progression
neurodegenerative
state.
In
this
context,
exercise
known
be
effective
non-pharmacological
management
strategy
can
counteract
decline
However,
concentration
fluid
in
patients
undergoing
protocols
has
led
unclear
often
conflicting
results,
suggesting
need
clarify
role
modulating
AD.
Therefore,
critical
literature
review
aims
gather
evidence
main
modulatory
effects
efficacy
usefulness
counteracting
neurodegeneration
Nature Communications,
Journal Year:
2023,
Volume and Issue:
14(1)
Published: Oct. 24, 2023
Abstract
Plasma
amyloid-β
(Aβ)42,
phosphorylated
tau
(p-tau)181,
and
neurofilament
light
chain
(NfL)
are
promising
biomarkers
of
Alzheimer’s
disease
(AD).
However,
whether
these
can
predict
AD
in
Chinese
populations
is
yet
to
be
fully
explored.
We
therefore
tested
the
performance
plasma
126
participants
with
preclinical
123
controls
8–10
years
follow-up
from
China
Cognition
Aging
Study.
Aβ42,
p-tau181,
NfL
were
significantly
correlated
cerebrospinal
fluid
counterparts
altered
AD.
Combining
successfully
discriminated
controls.
These
findings
validated
a
replication
cohort
including
51
familial
mutation
carriers
52
non-carriers
Familial
Disease
Network.
Here
we
show
that
may
useful
for
predicting
8
before
clinical
onset
populations.
Biosensors,
Journal Year:
2025,
Volume and Issue:
15(2), P. 85 - 85
Published: Feb. 4, 2025
Alzheimer’s
disease
(AD)
is
a
prevalent
neurodegenerative
disorder
and
significant
cause
of
dementia
in
elderly
individuals,
with
growing
prevalence
our
aging
population.
Extracellular
amyloid-β
peptides
(Aβ),
intracellular
tau
proteins,
their
phosphorylated
forms
have
gained
prominence
as
critical
biomarkers
for
early
precise
diagnosis
AD,
correlating
progression
response
to
therapy.
The
high
costs
invasiveness
conventional
diagnostic
methods,
such
positron
emission
tomography
(PET)
magnetic
resonance
imaging
(MRI),
limit
suitability
large-scale
or
routine
screening.
However,
electrochemical
(EC)
analysis
methods
made
progress
detection
due
sensitivity,
excellent
specificity,
portability,
cost-effectiveness.
This
article
reviews
the
EC
biosensing
technologies,
focusing
on
protein
blood
(a
low-invasive,
accessible
medium).
then
discusses
various
sensing
platforms,
including
fabrication
processes,
(LOD),
clinical
potential
show
role
these
sensors
transformers
changing
face
AD
diagnostics.
Journal of the Formosan Medical Association,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Jan. 1, 2024
Blood-based
biomarkers
(BBM)
are
potentially
powerful
tools
that
assist
in
the
biological
diagnosis
of
Alzheimer's
disease
(AD)
vivo
with
minimal
invasiveness,
relatively
low
cost,
and
good
accessibility.
This
review
summarizes
current
evidence
for
using
BBMs
AD,
focusing
on
amyloid,
tau,
neurodegeneration.
phosphorylated
tau
Aβ42/Aβ40
ratio
showed
consistent
concordance
brain
pathology
measured
by
CSF
or
PET
research
setting.
In
addition,
glial
fibrillary
acidic
protein
(GFAP)
neurofilament
light
chain
(NfL)
neurodegenerative
show
potential
to
differential
AD.
Other
pathology-specific
biomarkers,
such
as
α-synuclein
TAR
DNA-binding
43
(TDP-43),
can
detect
AD
concurrent
pathology.
Based
evidence,
working
group
from
Taiwan
Dementia
Society
(TDS)
achieved
consensus
recommendations
appropriate
use
clinical
practice.
may
prognosis
subjects
cognitive
symptoms;
however,
results
should
be
interpreted
dementia
specialists
combining
biochemical,
neuropsychological,
neuroimaging
information.
Further
studies
needed
evaluate
BBMs'
real-world
performance
impact
decision-making.
Frontiers in Aging Neuroscience,
Journal Year:
2025,
Volume and Issue:
17
Published: Jan. 20, 2025
Objective
This
study
investigates
the
interplay
between
muscle
strength,
information
processing
speed,
EEG-specific
biomarkers,
and
cognitive
function
in
elderly
individuals
with
impairments,
emphasizing
mediating
roles
of
speed
biomarkers.
Method
A
cross-sectional
design
was
employed
to
recruit
151
participants.
The
participants
underwent
grip
strength
30-s
sit-to-stand
tests
assess
completed
Trail
Making
Test
part
(TMT-A)
Symbol
Digit
Modality
(SDMT)
evaluate
utilized
Montreal
Cognitive
Assessment
(MOCA)
gauge
function.
Additionally,
EEG
signals
were
recorded
for
5
min
capture
neural
activity.
Results
difference
among
varying
degrees
impairment
statistically
significant
(
p
<
0.001).
negative
correlation
observed
MoCA
score
time
consumption
TMT-A
r
=
−0.402,
0.01),
a
positive
found
SDMT
0.609,
0.01).
Grip
negatively
correlated
−0.336,
0.01)
positively
0.336,
test
−0.273,
0.372,
we
that
α1
power
value
indicators
significantly
score,
TMT-A,
(all
values
at
F7
+
F8
T5
T6
identified
as
sensitive
speed.
B
0.019,
95%
CI:
0.003,
0.047)
0.137,
0.096,
0.292)
partially
mediate
relationship
scores,
exerting
stronger
effect.
Conclusion
Specific
patterns
which
could
objectively
risk
decline
this
population.
Muscle
biomarkers
closely
associated
individuals.
potential
pathway
interaction—muscle
→
function—provides
valuable
insights
into
advancing
field
research
elderly.
